SCHEMBL13614900

SCHEMBL13614900

c1ccc(-c2cccc(-c3c4ccccc4c(-c4ccc(-c5nc6ccccc6nc5-c5ccc(-c6c7ccccc7c(-c7cccc(-c8ccccc8)c7)c7ccccc67)cc5)cc4)c4ccccc34)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.51
LMNA P02545 4/20 0.51
KDM4E B2RXH2 4/20 0.51
TDP1 Q9NUW8 2/20 0.51
KMT2A Q03164 2/20 0.51
GAA P10253 1/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 3/20 0.47
ESR1 P03372 2/20 0.47
ESR2 Q92731 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
THRB P10828 1/20 0.46
DHODH Q02127 2/20 0.45
AKT1 P31749 1/20 0.45
AKT2 P31751 1/20 0.45
ATM Q13315 1/20 0.45
TLR9 Q9NR96 1/20 0.45
PKM P14618 1/20 0.44
ADORA2A P29274 1/20 0.42
NUDT1 P36639 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13614893 0.91 L3MBTL1 (0.60) L3MBTL1LMNAKDM4ETDP1KMT2A
SCHEMBL22470183 0.89 L3MBTL1 (0.62) L3MBTL1LMNAKDM4ETDP1KMT2A
SCHEMBL1766036 0.89 L3MBTL1 (0.62) L3MBTL1LMNAKDM4ETDP1KMT2A
SCHEMBL22186468 0.88 KDM4E (0.64) L3MBTL1LMNAKDM4ETDP1KMT2A
SCHEMBL24433111 0.87 CYP11B1 (0.48) L3MBTL1LMNAKDM4ETDP1KMT2A
SCHEMBL23607175 0.86 ESR1 (0.44) L3MBTL1LMNAKDM4ETDP1KMT2A
SCHEMBL22470168 0.86 LMNA (0.47) L3MBTL1LMNAKDM4ETDP1KMT2A
SCHEMBL18504119 0.84 KDM4E (0.59) L3MBTL1LMNAKDM4ETDP1KMT2A
SCHEMBL19009635 0.83 ESR1 (0.44) L3MBTL1LMNAKDM4EALDH1A1ESR1
SCHEMBL19009596 0.83 L3MBTL1 (0.45) L3MBTL1LMNAKDM4ETDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612204-B2 Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-11-03 US disclosed
US-7612204-B2 Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-11-03 US disclosed
US-20080091012-A1 Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-17 US disclosed
US-20080091012-A1 Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080091012-A1 Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative NQO1, GLB1, PDXK L3MBTL1 1370/4885LMNA 3244/4885KDM4E 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.